SCHEMBL19969154

SCHEMBL19969154

CN(C(=O)C(Cc1cc(F)cc(F)c1)NS(=O)(=O)NC(=O)N[C@@H](Cc1cc(F)cc(F)c1)C(=O)N(C)c1ccc(F)c(F)c1)c1ccc(F)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 2/20 0.35
PSMB1 P20618 1/20 0.35
PSMB2 P49721 1/20 0.35
CA12 O43570 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
PYGL P06737 1/20 0.33
ANPEP P15144 2/20 0.32
KDM1A O60341 1/20 0.32
MAOA P21397 1/20 0.32
FOLH1 Q04609 1/20 0.31
NR3C1 P04150 1/20 0.30
PGR P06401 1/20 0.30
NR3C2 P08235 1/20 0.30
MEN1 O00255 1/20 0.30
POLB P06746 1/20 0.30
HTT P42858 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19962156 1.00 PSMB5 (0.35) PSMB5PSMB1PSMB2CA12CA7
SCHEMBL19962134 0.91 ALDH1A1 (0.34) CA12CA7CA9CA14PYGL
SCHEMBL18180059 0.89 CYP3A4 (0.37) PSMB5CA12CA7CA9CA14
SCHEMBL19962136 0.89 CA12 (0.35) CA12CA7CA9CA14PYGL
SCHEMBL19969234 0.89 CA12 (0.41) CA12CA7CA9CA14PYGL
SCHEMBL18179923 0.89 CA12 (0.41) CA12CA7CA9CA14PYGL
SCHEMBL19962055 0.88 MAPT (0.34) CA12CA7CA9CA14NR3C1
SCHEMBL18180321 0.87 F2 (0.37) CA12CA7CA9CA14PYGL
SCHEMBL18180411 0.87 ALDH1A1 (0.36) CA12CA7CA9CA14PYGL
SCHEMBL18180124 0.87 BMP1 (0.40) CA12CA7CA9CA14ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2H, POLR2E PSMB5 2506/4885PSMB1 2019/4885PSMB2 2777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.